Innate Pharma (IPHA) Short term Debt (2017 - 2025)
Innate Pharma's (IPHA) quarterly Short term Debt came in at $10.2 million in Q4 2025, up 10.1% YoY from $9.3 million in Q4 2024, and up 1.31% on a QoQ basis from $10.1 million in Q2 2025.
Innate Pharma (IPHA) Short term Debt (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Short term Debt data on file, last reported at $10.2 million in Q4 2025.
- Quarterly Short term Debt rose 10.1% year-over-year to $10.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.2 million (up 10.1% YoY) and the FY2025 annual result came in at $10.2 million, up 10.1% from the prior year.
- Short term Debt rose to $10.2 million in Q4 2025, from $10.1 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $35.2 million in Q4 2021 to a low of $2.1 million in Q4 2022.
- A 5-year average of $12.7 million and a median of $9.6 million in 2023 frame the typical range for Short term Debt.
- The widest YoY moves for Short term Debt: up 1277.31% in 2021, down 99.88% in 2021.
- Tracing IPHA's Short term Debt over 5 years: stood at $35.2 million in 2021, then tumbled by 93.9% to $2.1 million in 2022, then soared by 348.33% to $9.6 million in 2023, then slipped by 3.21% to $9.3 million in 2024, then rose by 10.1% to $10.2 million in 2025.
- The last three Short term Debt figures came in at $10.2 million (Q4 2025), $10.1 million (Q2 2025), and $9.3 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.25 Mn |
| Jun 30, 2025 | 10.11 Mn |
| Dec 31, 2024 | 9.31 Mn |
| Jun 30, 2024 | 9.62 Mn |
| Dec 31, 2023 | 9.61 Mn |
| Jun 30, 2023 | 5.81 Mn |
| Dec 31, 2022 | 2.14 Mn |
| Jun 30, 2022 | 32.92 Mn |
| Dec 31, 2021 | 35.17 Mn |
| Jun 30, 2021 | 2.43 Mn |
| Dec 31, 2020 | 2.55 Mn |
| Jun 30, 2020 | 2.04 Bn |
| Dec 31, 2019 | 2.36 Mn |
| Dec 31, 2018 | 1.90 Mn |
| Dec 31, 2017 | 1.58 Mn |